Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple myeloma
- New trial Spotlight
Multiple myeloma
Phase 3 JNJ-79635322 BCMA/GPRC5D×CD3 trispecific antibody vs teclistamab BCMA×CD3 bispecific in RRMM
Janssen Research & Development (Johnson & Johnson) is running this Phase 3 randomized head-to-head study (TRIlogy-5) to compare JNJ-79635322 versus teclistamab in relapsed/refractory multiple myeloma after 1–3 prior…
NCT07518186 Registrational - New trial
Multiple myeloma
Phase 3 isatuximab (anti-CD38 mAb) + iberdomide (CRBN E3 ligase modulator) in transplant-eligible NDMM
Dana-Farber Cancer Institute’s randomized DETERMINATION 2 program tests whether a risk- and MRD/response-adapted strategy can improve outcomes for newly diagnosed, transplant-eligible multiple myeloma. Everyone…
NCT07624513 Exploratory - New trial
Multiple myeloma
Phase 3 cevostamab FCRH5×CD3 bispecific antibody plus Pd in relapsed multiple myeloma
Hoffmann‑La Roche/Genentech’s CEVOLUTION (Phase 3) is a randomized, open-label, multicenter study testing cevostamab + pomalidomide + dexamethasone (CevosPd) versus investigator’s choice standard regimens in…
NCT07555938 Registrational - New trial
Multiple myeloma
Phase 1b/2 isatuximab + iberdomide cereblon E3-ligase modulator combo in NDMM
Dana-Farber Cancer Institute is running this Phase 1b/2, open-label study testing a four-drug induction regimen—isatuximab (Sanofi; CD38-directed monoclonal antibody), iberdomide (Bristol Myers Squibb/Celgene;…
NCT07601100 Exploratory - New trial Spotlight
Multiple myeloma
Phase 2 Linvoseltamab BCMA×CD3 bispecific T‑cell engager vs Isa‑KRd + ASCT in high‑risk NDMM.
MMRC Horizon Two (NCT07053436) is an open-label, randomized, adaptive platform Phase 2 trial in transplant-eligible, high-risk newly diagnosed multiple myeloma with measurable, symptomatic disease. The shared control…
NCT07053436 Exploratory - New trial
Multiple myeloma
Phase 1b sirolimus mTOR inhibitor pre-conditioning plus BCMA×CD3 or GPRC5D×CD3 bispecifics in relapsed/refractory myeloma.
This single-center, single-arm Phase 1b study with an expansion cohort tests whether short-course sirolimus (an mTOR pathway inhibitor that can reshape T-cell activation/exhaustion programs) can “pre-condition” the…
NCT07581704 Exploratory - New trial
Multiple myeloma
Phase 1b/2 selinexor XPO1 (SINE) inhibitor plus carfilzomib proteasome inhibitor in RRMM
This Phase 1b/2, open-label combination study evaluates selinexor (Karyopharm; an oral XPO1/exportin-1 selective inhibitor of nuclear export) with carfilzomib (Amgen; selective, irreversible proteasome inhibitor),…
NCT07479979 Exploratory - Trial result
Multiple myeloma
Daratumumab (CD38) + ixazomib (oral proteasome inhibitor) sans dexamethasone delivers 19.5-mo PFS in frail elderly RRMM
Daratumumab is an anti-CD38 monoclonal antibody and ixazomib is an oral proteasome inhibitor; IFM 2018-02 (NCT03757221) tested this dexamethasone-free doublet (with methylprednisolone premedication) in a prospective…
NCT03757221 - New trial
Multiple myeloma
Phase 2 DREAMM-15: belantamab mafodotin BCMA-targeting MMAF ADC in RRMM combinations
GlaxoSmithKline’s DREAMM-15 is a Phase 2, multicenter, open-label, non-randomized study testing extended-interval dosing of belantamab mafodotin (Blenrep)—a BCMA-directed antibody–drug conjugate delivering MMAF, a…
NCT07227311 Exploratory - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 100% MRD(10⁻⁶) negativity by 2 months in high-risk SMM
Ciltacabtagene autoleucel (cilta-cel) is a BCMA-targeted autologous CAR-T; in the CAR-PRISM Phase 2 trial (NCT05767359), HR-SMM patients received a single cilta-cel infusion (0.3–0.5×10⁶ or >0.5×10⁶ viable CAR+ T…
NCT05767359 - New trial Spotlight
Multiple myeloma
Phase 1 KLN-1010 anti-BCMA CAR gene therapy (in vivo CAR‑T generation)
This first-in-human, open-label, sequential-assignment Phase 1 trial tests KLN-1010, a one-time IV *in vivo* gene therapy intended to generate anti-BCMA CAR‑T cells inside the patient (rather than collecting and…
NCT07075185 First-in-human - New trial
Multiple myeloma
Phase 2 inobrodib (CCS1477) p300/CBP bromodomain inhibitor with Pd in R/R myeloma.
This Phase 2, open-label, multicenter, single-arm study (no comparator) evaluates inobrodib in combination with pomalidomide and dexamethasone (often described as “InoPd”) in heavily pretreated relapsed/refractory…
NCT07096778 Exploratory - New trial
Multiple myeloma
Phase 1 PF-07994525 trial in R/R multiple myeloma
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07426757 First-in-human - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 71% 30‑mo PFS in standard‑risk lenalidomide‑refractory RRMM (CARTITUDE‑4)
Ciltacabtagene autoleucel (cilta-cel) is an autologous anti‑BCMA CAR‑T therapy evaluated in the randomized Phase 3 CARTITUDE‑4 trial (NCT04181827) in lenalidomide‑refractory relapsed/refractory multiple myeloma after…
NCT04181827 - Trial result Spotlight
Multiple myeloma
Cevostamab (FcRH5×CD3 bispecific) + pom-dex drives ~86–88% ORR and high MRD-negativity in BCMA-naïve RRMM
Cevostamab is an FcRH5×CD3 T-cell–engaging bispecific antibody; here it was combined with pomalidomide (IMiD) plus dexamethasone to augment T-cell activity in the Phase Ib CAMMA 1 Arm B randomized dose-expansion…
NCT04910568 - Trial result
Multiple myeloma
D-VRd (daratumumab anti-CD38) drives 65% sustained MRD− and >95% 4-year PFS in TE NDMM
Subcutaneous daratumumab (anti-CD38 mAb) plus bortezomib/lenalidomide/dexamethasone (D-VRd) with daratumumab+lenalidomide (D-R) maintenance was evaluated vs VRd with lenalidomide maintenance in the Phase 3 PERSEUS…
NCT03710603 - New trial
Multiple myeloma
Phase 1/2 ABBV-453 (BCL-2 inhibitor) ± daratumumab/dexamethasone (± pomalidomide) in R/R MM
AbbVie tests ABBV-453 across dose-escalation/expansion, alone and on CD38/IMiD backbones (with a Japanese monotherapy cohort). Late-line MM cycles through IMiDs/PIs/anti-CD38, with venetoclax often used off-label in…
NCT06953960 First-in-human - New trial Spotlight
Multiple myeloma
Phase Ib Talquetamab bispecific targeting GPRC5D/CD3 and Cilta-cel CAR-T (BCMA) in RRMM
This single-arm Phase 1b trial by the Medical College of Wisconsin evaluates the safety and feasibility of using talquetamab—a bispecific antibody targeting GPRC5D and CD3—as bridging therapy during CAR T-cell…
NCT07093554 Exploratory - New trial Spotlight
Multiple myeloma
Phase 3 Belantamab Mafodotin Trial – BCMA-targeting ADC in Transplant-Ineligible Myeloma
This Phase 3 randomized, open-label trial at GlaxoSmithKline compares belantamab mafodotin (a BCMA-directed antibody-drug conjugate with a tubulin inhibitor payload) plus lenalidomide and dexamethasone versus…
NCT06679101 Registrational - New trial
Multiple myeloma
Phase 1/2 mRNA-2808 mRNA gene therapy vaccine for relapsed/refractory multiple myeloma
This open-label, multicenter study led by ModernaTX assesses the safety and tolerability of mRNA-2808, an mRNA vaccine using an undisclosed antigen, in adults with relapsed or refractory multiple myeloma.…
NCT07116616 First-in-human - New trial
Multiple myeloma
Phase 1b teclistamab (BCMA/CD3 bispecific antibody) and mezigdomide (cereblon modulator) for relapsed/refractory multiple myeloma.
This Phase 1b study led by Memorial Sloan Kettering is evaluating the safety and effectiveness of combining teclistamab and mezigdomide in patients with relapsed/refractory multiple myeloma who have received at least…
NCT07105059 Exploratory - New trial Spotlight
Multiple myeloma
Phase I Trial of GB1211 (Oral Galectin-3 Inhibitor) in Multiple Myeloma
This study is designed to evaluate the safety, tolerability, and optimal dosing of selvigaltin, a galectin-3 blocker, when combined with daratumumab-hyaluronidase, carfilzomib, and dexamethasone in patients with…
NCT07082270 First-in-human - New trial Spotlight
Multiple myeloma
Phase 1 GC012F Dual CAR T-cell Therapy Targeting CD19 and BCMA for Multiple Myeloma
This phase 1 study is investigating GC012F in early-line treatment for multiple myeloma, including newly diagnosed high-risk and relapsed/refractory cases. The trial uses a single infusion of a dual CAR T-cell…
NCT07073547 First-in-human - New trial
Multiple myeloma
Phase 1 trial: Mezigdomide (cereblon E3 ligase modulator) & Talquetamab (GPRC5D/CD3 bispecific mAb)
This study by Massachusetts General Hospital evaluates optimal dosing and scheduling of mezigdomide and talquetamab in patients with relapsed/refractory multiple myeloma after four or more therapies. Two sequential…
NCT07032714 Exploratory - New trial
Multiple myeloma
Phase II Trial of Elranatamab, a BCMA/CD3 bispecific antibody, in newly diagnosed multiple myeloma.
This open-label, multi-site study by SCRI Development Innovations, LLC compares consolidation and maintenance strategies after induction therapy in newly diagnosed multiple myeloma patients. In Arm A, patients…
NCT06974786 Exploratory - New trial Spotlight
Multiple myeloma
Phase 2 teclistamab bispecific BCMA/CD3 antibody trial in high-risk multiple myeloma
This open-label Phase 2 trial investigates sequencing of teclistamab, daratumumab, and talquetamab—with or without melphalan transplant—for newly diagnosed high-risk multiple myeloma patients stratified by minimal…
NCT07029776 Exploratory - New trial
Multiple myeloma
Phase 2 linvoseltamab: BCMA and CD3 bispecific antibody
This phase 2 study evaluates the safety and efficacy of linvoseltamab in multiple myeloma patients relapsed after BCMA CAR T-cell therapy. All subjects receive an initial inpatient step-up dosing regimen followed by…
NCT07009899 Exploratory - New trial
Multiple myeloma
Phase 1/2 Belantamab Mafodotin, a BCMA-targeted tubulin inhibitor ADC study
This trial evaluates escalating doses of belantamab alone or combined with belantamab mafodotin for relapsed/refractory multiple myeloma patients (≥4 prior therapies). Sponsored by GlaxoSmithKline, the multicentre…
NCT05714839 Exploratory - Trial result
Multiple myeloma
Isatuximab-VRd Boosts PET-/MRD- “Double Negativity” and Delays Progression vs VRd in Transplant-Ineligible NDMM
In the phase 3 IMROZ trial (NCT03319667), 406 transplant-ineligible, newly diagnosed myeloma patients with baseline PET/CT (Isa-VRd n=244; VRd n=162) received quadruplet induction (isatuximab…
NCT03319667 - Trial result
Multiple myeloma
Isa-KRd Consolidation Rivals Up-Front Transplant for 10-6 MRD Clearance in Newly Diagnosed Myeloma
Measurable-residual-disease–guided phase 3 MIDAS trial (NCT04934475) randomized 718 transplant-eligible NDMM patients after Isa-KRd induction by post-induction MRD10-5 status. In MRD-negative (n = 485) disease, deep…
NCT04934475
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.